+16.5%
VXUS vs MRNA
+945.0%
-928.5%
-11.3%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +2.0% | +13.1% | -11.1% | +1.8% |
| 7D | +0.2% | +20.6% | -20.5% | -0.1% |
| 30D | -2.3% | +27.1% | -29.4% | -2.7% |
| 3M | -2.8% | +353.4% | -356.2% | -6.5% |
| 6M | +2.6% | +446.3% | -443.6% | -3.8% |
| YTD | +12.0% | +776.2% | -764.2% | +2.5% |
| 1Y | +16.5% | +987.9% | -971.4% | +3.3% |
| All | +16.5% | +945.0% | -928.5% | +3.3% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling